ArticleBioMed research international2014
Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- DNA methylation markers for oral cancer detection in non- and minimally invasive samples: a systematic review.Clinical epigenetics · 2024Pooled it
- Diagnostic accuracy of DNA methylation for head and neck cancer varies by sample type and number of markers tested.Oncotarget · 2016Pooled it
- Association between P16INK4a promoter methylation and HNSCC: a meta-analysis of 21 published studies.PloS one · 2015Pooled it
- Aberrant DNA methylation of EDNRB, MGMT and TIMP3 gene promoters in saliva of head and neck carcinoma patients as a diagnostic tool.Molecular biology reports · 2025Article
- Identification and validation of a novel risk model based on cuproptosis‑associated m6A for head and neck squamous cell carcinoma.BMC medical genomics · 2024Article
- Salivary Biomarkers for Oral Cancer Detection: Insights from Human DNA and RNA Analysis.Cardiovascular & hematological agents in medicinal chemistry · 2024Review
- Expression Profiles ofBiomedicines · 2022Article
- An Overview of DNA Methylation Indicators for the Course of Oral Precancer.Applied bionics and biomechanics · 2022Review
- Review
- Saliva Gene Promoter Hypermethylation as a Biomarker in Oral Cancer.Journal of clinical medicine · 2021Review
- Molecular biology of oral cavity squamous cell carcinoma.Oral oncology · 2020Article
- Promoter DNA Methylation and mRNA Expression Level of p16 Gene in Oral Squamous Cell Carcinoma: Correlation with Clinicopathological Characteristics.Pathology oncology research : POR · 2019Article
- Leveraging Genomics for Head and Neck Cancer Treatment.Journal of dental research · 2018Review
- Article
- Aberrant DNA methylation of theJournal of Cancer · 2018Article
- DNA methylation markers for oral pre-cancer progression: A critical review.Oral oncology · 2016Review
- Molecular Mechanisms of Malignant Transformation by Low Dose Cadmium in Normal Human Bronchial Epithelial Cells.PloS one · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Promoter methylation and relative gene expression of O(6)-methyguanine-DNA-methyltransferase (MGMT) and p16 genes were examined in tissue and blood samples of patients with premalignant oral lesions (PMOLs) and oral squamous cell carcinoma (OSCC). Methylation-specific PCR and reverse transcriptase PCR were performed in 146 tissue and blood samples from controls and patients with PMOLs and OSCC. In PMOL group, significant promoter methylation of MGMT and p16 genes was observed in 59% (P = 0.0010) and 57% (P = 0.0016) of tissue samples, respectively, and 39% (P = 0.0135) and 33% (P = 0.0074) of blood samples, respectively. Promoter methylation of both genes was more frequent in patients with OSCC, that is, 76% (P = 0.0001) and 82% (P = 0.0001) in tissue and 57% (P = 0.0002) and 70% (P = 0.0001) in blood, respectively. Significant downregulation of MGMT and p16 mRNA expression was observed in both tissue and blood samples from patients with PMOLs and OSCC. Hypermethylation-induced transcriptional silencing of MGMT and p16 genes in both precancer and cancer suggests important role of these changes in progression of premalignant state to malignancy. Results support use of blood as potential surrogate to tissue samples for screening or diagnosing PMOLs and early OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.